Sutro Biopharma, Inc. (STRO) Financial Ratios
9 years of historical data (2016–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low1.9·High1.9
P/B Ratio
↑
6.86
↑+2850% vs avg
5yr avg: 0.23
30Y Low0.2·High0.3
ROE
↓
-234.2%
↑-197% vs avg
5yr avg: -78.9%
30Y Low-313%·High-15%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.2·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
STRO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sutro Biopharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $338M | $14M | $26M | $41M | $69M | $71M | $25M | $21M | — | — |
| Enterprise Value | $171M | $-153013427 | $-9822841 | $49M | $96M | $-110889997 | $30M | $-89949698 | — | — |
| P/E Ratio → | -1.35 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 5.45 | 0.23 | 0.17 | 0.60 | 1.11 | 1.66 | 0.59 | 0.54 | — | — |
| P/B Ratio | 6.86 | 0.32 | 0.17 | 0.19 | 0.27 | 0.21 | 0.26 | 0.16 | — | — |
| P/FCF | — | — | — | — | — | — | — | 1.85 | — | — |
| P/OCF | — | — | — | 11.55 | — | — | — | 1.63 | — | — |
P/E links to full P/E history page with 30-year chart
STRO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -2.47 | -0.06 | 0.72 | 1.54 | -2.60 | 0.71 | -2.34 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | -8.08 | — | — |
STRO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sutro Biopharma, Inc. earns an operating margin of -384.3%. Operating margins have compressed from -190.3% to -384.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -234.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.4% | 88.4% | 95.6% | 87.8% | 84.2% | -80.1% | 100.0% | -41.2% | -0.3% | 27.1% |
| Operating Margin | -384.3% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | -129.8% | -96.9% | -37.2% | 2.3% |
| Net Profit Margin | -366.6% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | -130.4% | -91.9% | -38.1% | 2.8% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -234.2% | -234.2% | -58.2% | -50.8% | -36.1% | -14.9% | -48.6% | -313.4% | — | — |
| ROA | -53.0% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | -29.4% | -26.8% | -35.8% | 2.5% |
| ROIC | — | — | -39.5% | -38.4% | -34.4% | -42.1% | -67.3% | — | — | — |
| ROCE | -75.4% | -75.4% | -24.9% | -40.3% | -29.7% | -29.1% | -35.8% | -38.1% | -138.1% | 7.1% |
STRO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $190M exceeds total debt of $23M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.52 | 0.52 | 0.22 | 0.25 | 0.23 | 0.07 | 0.10 | 0.11 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.17 |
| Net Debt / Equity | — | -3.75 | -0.24 | 0.04 | 0.11 | -0.55 | 0.05 | -0.84 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -1.48 |
| Debt / FCF | — | — | — | — | — | — | — | -9.94 | — | — |
| Interest Coverage | -7.67 | -7.67 | -3.76 | -38.54 | -31.41 | -17.88 | -12.75 | -23.26 | -27.97 | — |
Net cash position: cash ($190M) exceeds total debt ($23M)
STRO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Sutro Biopharma, Inc.'s current ratio of 2.60x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.31x to 2.60x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.60 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 | 0.99 |
| Quick Ratio | 2.60 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 | 0.99 |
| Cash Ratio | 2.40 | 2.40 | 4.01 | 5.02 | 4.74 | 12.44 | 3.58 | 5.61 | 0.69 | 0.95 |
| Asset Turnover | — | 0.16 | 0.33 | 0.17 | 0.18 | 0.11 | 0.27 | 0.17 | 1.27 | 0.86 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 50.69 | 85.66 | 38.36 | 73.46 | 47.49 | 53.79 | 23.65 | 11.46 | 3.53 |
STRO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sutro Biopharma, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 53.9% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.3% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.3% | 0.0% | — | — |
| Shares Outstanding | — | $8M | $6M | $5M | $5M | $3M | $2M | $2M | $699739 | $44120 |
Peer Comparison
Compare STRO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 STROYou | $338M | -1.3 | — | — | 88.4% | -384.3% | -234.2% | — | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 BOLT | $9M | -0.3 | — | — | — | -469.3% | -79.7% | -48.0% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 CRIS | $76M | -1.0 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 PBYI | $369M | 11.9 | 7.6 | 8.9 | 74.5% | 16.3% | 28.0% | 24.7% | 0.6 |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See STRO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STRO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare STRO vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonSTRO — Frequently Asked Questions
Quick answers to the most common questions about buying STRO stock.
What is Sutro Biopharma, Inc.'s P/E ratio?
Sutro Biopharma, Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
What is Sutro Biopharma, Inc.'s ROE?
Sutro Biopharma, Inc.'s return on equity (ROE) is -234.2%. The historical average is -108.0%.
Is STRO stock overvalued?
Based on historical data, Sutro Biopharma, Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Sutro Biopharma, Inc.'s profit margins?
Sutro Biopharma, Inc. has 88.4% gross margin and -384.3% operating margin.